Utilizing sparsentan may reduce the risk of death and kidney failure in FSGS patients.

Published Date: 05 Nov 2023

The DUPLEX trial failed to reach its primary endpoint of eGFR slope in FSGS patients; however, results indicate that sparsentan use reduces proteinuria and kidney failure risk more than irbesartan use does, thus supporting sparsentan as a standard treatment for glomerular disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot